Literature DB >> 23079661

Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia.

Xi Jiang1, Hao Huang, Zejuan Li, Yuanyuan Li, Xiao Wang, Sandeep Gurbuxani, Ping Chen, Chunjiang He, Dewen You, Shuodan Zhang, Jinhua Wang, Stephen Arnovitz, Abdel Elkahloun, Colles Price, Gia-Ming Hong, Haomin Ren, Rejani B Kunjamma, Mary Beth Neilly, Jonathan M Matthews, Mengyi Xu, Richard A Larson, Michelle M Le Beau, Robert K Slany, Paul P Liu, Jun Lu, Jiwang Zhang, Chuan He, Jianjun Chen.   

Abstract

Expression of microRNAs (miRNAs) is under stringent regulation at both transcriptional and posttranscriptional levels. Disturbance at either level could cause dysregulation of miRNAs. Here, we show that MLL fusion proteins negatively regulate production of miR-150, an miRNA widely repressed in acute leukemia, by blocking miR-150 precursors from being processed to mature miRNAs through MYC/LIN28 functional axis. Forced expression of miR-150 dramatically inhibited leukemic cell growth and delayed MLL-fusion-mediated leukemogenesis, likely through targeting FLT3 and MYB and thereby interfering with the HOXA9/MEIS1/FLT3/MYB signaling network, which in turn caused downregulation of MYC/LIN28. Collectively, we revealed a MLL-fusion/MYC/LIN28miR-150FLT3/MYB/HOXA9/MEIS1 signaling circuit underlying the pathogenesis of leukemia, where miR-150 functions as a pivotal gatekeeper and its repression is required for leukemogenesis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23079661      PMCID: PMC3480215          DOI: 10.1016/j.ccr.2012.08.028

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  50 in total

Review 1.  Posttranscriptional regulation of microRNA biogenesis in animals.

Authors:  Haruhiko Siomi; Mikiko C Siomi
Journal:  Mol Cell       Date:  2010-05-14       Impact factor: 17.970

Review 2.  Emerging paradigms of regulated microRNA processing.

Authors:  Martin A Newman; Scott M Hammond
Journal:  Genes Dev       Date:  2010-06-01       Impact factor: 11.361

3.  Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.

Authors:  Thomas A Milne; Mary Ellen Martin; Hugh W Brock; Robert K Slany; Jay L Hess
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

4.  c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells.

Authors:  Jay L Hess; Claudia B Bittner; Deniz T Zeisig; Christian Bach; Uta Fuchs; Arndt Borkhardt; Jon Frampton; Robert K Slany
Journal:  Blood       Date:  2006-02-28       Impact factor: 22.113

5.  MLL associates specifically with a subset of transcriptionally active target genes.

Authors:  Thomas A Milne; Yali Dou; Mary Ellen Martin; Hugh W Brock; Robert G Roeder; Jay L Hess
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells.

Authors:  Li Li; Obdulio Piloto; Kyu-Tae Kim; Zhaohui Ye; Ho Bao Nguyen; Xiaobing Yu; Mark Levis; Linzhao Cheng; Donald Small
Journal:  Br J Haematol       Date:  2007-04       Impact factor: 6.998

7.  Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.

Authors:  Gang G Wang; Martina P Pasillas; Mark P Kamps
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

8.  MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb.

Authors:  Changchun Xiao; Dinis Pedro Calado; Gunther Galler; To-Ha Thai; Heide Christine Patterson; Jing Wang; Nikolaus Rajewsky; Timothy P Bender; Klaus Rajewsky
Journal:  Cell       Date:  2007-10-05       Impact factor: 41.582

Review 9.  FLT3 as a therapeutic target in childhood acute leukemia.

Authors:  Matthew C Stubbs; Scott A Armstrong
Journal:  Curr Drug Targets       Date:  2007-06       Impact factor: 3.465

10.  ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.

Authors:  Deepa B Shankar; Junling Li; Paul Tapang; J Owen McCall; Lori J Pease; Yujia Dai; Ru-Qi Wei; Daniel H Albert; Jennifer J Bouska; Donald J Osterling; Jun Guo; Patrick A Marcotte; Eric F Johnson; Niru Soni; Kresna Hartandi; Michael R Michaelides; Steven K Davidsen; Saul J Priceman; Jenny C Chang; Katrin Rhodes; Neil Shah; Theodore B Moore; Kathleen M Sakamoto; Keith B Glaser
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

View more
  102 in total

1.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.

Authors:  Sun-Mi Park; Mithat Gönen; Ly Vu; Gerard Minuesa; Patrick Tivnan; Trevor S Barlowe; James Taggart; Yuheng Lu; Raquel P Deering; Nir Hacohen; Maria E Figueroa; Elisabeth Paietta; Hugo F Fernandez; Martin S Tallman; Ari Melnick; Ross Levine; Christina Leslie; Christopher J Lengner; Michael G Kharas
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

2.  Role of microRNA-150 in solid tumors.

Authors:  Fang Wang; Xiubao Ren; Xinwei Zhang
Journal:  Oncol Lett       Date:  2015-04-30       Impact factor: 2.967

Review 3.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

4.  Mechanisms of mixed-lineage leukemia.

Authors:  Andrew G Muntean
Journal:  Int J Hematol Oncol       Date:  2013-06-01

Review 5.  MicroRNAs in B-cell lymphomas: how a complex biology gets more complex.

Authors:  K Musilova; M Mraz
Journal:  Leukemia       Date:  2014-12-26       Impact factor: 11.528

6.  FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase.

Authors:  Zejuan Li; Hengyou Weng; Rui Su; Xiaocheng Weng; Zhixiang Zuo; Chenying Li; Huilin Huang; Sigrid Nachtergaele; Lei Dong; Chao Hu; Xi Qin; Lichun Tang; Yungui Wang; Gia-Ming Hong; Hao Huang; Xiao Wang; Ping Chen; Sandeep Gurbuxani; Stephen Arnovitz; Yuanyuan Li; Shenglai Li; Jennifer Strong; Mary Beth Neilly; Richard A Larson; Xi Jiang; Pumin Zhang; Jie Jin; Chuan He; Jianjun Chen
Journal:  Cancer Cell       Date:  2016-12-22       Impact factor: 31.743

7.  LncRNA H19-elevated LIN28B promotes lung cancer progression through sequestering miR-196b.

Authors:  Jin Ren; Jinling Fu; Tiangang Ma; Bingdi Yan; Rong Gao; Zhe An; Dan Wang
Journal:  Cell Cycle       Date:  2018-07-23       Impact factor: 4.534

8.  Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9.

Authors:  Seiko Yoshino; Takashi Yokoyama; Yoshitaka Sunami; Tomoko Takahara; Aya Nakamura; Yukari Yamazaki; Shuichi Tsutsumi; Hiroyuki Aburatani; Takuro Nakamura
Journal:  Blood       Date:  2021-01-07       Impact factor: 22.113

9.  Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

Authors:  Zejuan Li; Tobias Herold; Chunjiang He; Peter J M Valk; Ping Chen; Vindi Jurinovic; Ulrich Mansmann; Michael D Radmacher; Kati S Maharry; Miao Sun; Xinan Yang; Hao Huang; Xi Jiang; Maria-Cristina Sauerland; Thomas Büchner; Wolfgang Hiddemann; Abdel Elkahloun; Mary Beth Neilly; Yanming Zhang; Richard A Larson; Michelle M Le Beau; Michael A Caligiuri; Konstanze Döhner; Lars Bullinger; Paul P Liu; Ruud Delwel; Guido Marcucci; Bob Lowenberg; Clara D Bloomfield; Janet D Rowley; Stefan K Bohlander; Jianjun Chen
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

10.  miR-150 Regulates Memory CD8 T Cell Differentiation via c-Myb.

Authors:  Zeyu Chen; Erietta Stelekati; Makoto Kurachi; Sixiang Yu; Zhangying Cai; Sasikanth Manne; Omar Khan; Xiaolu Yang; E John Wherry
Journal:  Cell Rep       Date:  2017-09-12       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.